文献速递肺结节与肺癌

帕博利珠单抗联合或不联合放疗治疗转移性非小细胞肺癌:两项随机试验的汇总分析

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
PubMed 文献 · Lancet Respir Med · 2020-10-20

该汇总分析纳入PEMBRO-RT(2期)和MDACC(1/2期)两项随机试验的148例转移性NSCLC患者,比较帕博利珠单抗单用与联合放疗的疗效。

要点

  • 联合治疗未发现新的安全性问题,但需3期随机试验验证。

核心结论

  • 在转移性NSCLC患者中,帕博利珠单抗联合放疗较单药显著提高远隔效应缓解率和疾病控制率,并延长无进展生存期和总生存期。

研究设计与样本

  • 汇总分析PEMBRO-RT(2期)和MDACC(1/2期)两项随机试验,纳入148例免疫治疗初治的转移性NSCLC患者,76例接受帕博利珠单抗,72例接受帕博利珠单抗联合放疗。

主要发现

  • 汇总分析未发现新的安全性问题。

关键数值与推荐

  • 帕博利珠单抗用法:200 mg静脉注射,每3周一次。
  • PEMBRO-RT放疗方案:24 Gy分3次,末次放疗后1周内开始帕博利珠单抗。
  • MDACC放疗方案:50 Gy分4次或45 Gy分15次,与帕博利珠单抗首剂同步。
  • 仅测量未照射病灶以评估远隔效应。

临床怎么用

  • 对于免疫治疗初治的转移性NSCLC患者,可考虑帕博利珠单抗联合放疗以增强远隔效应并改善生存。
  • 联合治疗需关注放疗与免疫治疗的时序安排,如PEMBRO-RT采用序贯、MDACC采用同步模式。
  • 该结果尚需3期随机试验验证后方可改变临床实践。

局限性

  • 汇总分析基于两项样本量较小的早期试验,统计效能有限。
  • 两项试验的放疗剂量、分割方式及与免疫治疗的时序不同,可能影响结果一致性。
  • 联合治疗组因干预性质无法设盲。
  • 仅测量未照射病灶评估远隔效应,可能低估局部放疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-small-cell lung cancer were randomly allocated immunotherapy (pembrolizumab) with or without radiotherapy. When the trials were analysed individually, a potential benefit was noted in the combination treatment arm. However, owing to the small sample size of each trial, differences in response rates and outcomes were not statistically significant but remained clinically notable. We therefore did a pooled analysis to infer whether radiotherapy improves responses to immunotherapy in patients with metastatic non-small-cell lung cancer. METHODS: Inclusion criteria for the PEMBRO-RT and MDACC trials were patients (aged ≥18 years) with metastatic non-small-cell lung cancer and at least one unirradiated lesion to monitor for out-of-field response. In the PEMBRO-RT trial, patients had previously received chemotherapy, whereas in the MDACC trial, patients could be either previously treated or newly diagnosed. Patients in both trials were immunotherapy-naive. In the PEMBRO-RT trial, patients were randomly assigned (1:1) and stratified by smoking status (<10 vs ≥10 pack-years). In the MDACC trial, patients were entered into one of two cohorts based on radiotherapy schedule feasibility and randomly assigned (1:1). Because of the nature of the intervention in the combination treatment arm, blinding to radiotherapy was not feasible in either trial. Pembrolizumab was administered intravenously (200 mg every 3 weeks) with or without radiotherapy in both trials. In the PEMBRO-RT trial, the first dose of pembrolizumab was given sequentially less than 1 week after the last dose of radiotherapy (24 Gy in three fractions), whereas in the MDACC trial, pembrolizumab was given concurrently with the first dose of radiotherapy (50 Gy in four fractions or 45 Gy in 15 fractions). Only unirradiated lesions were measured for response. The endpoints for this pooled analysis were best out-of-field (abscopal) response rate (ARR), best abscopal disease control rate (ACR), ARR at 12 weeks, ACR at 12 weeks, progression-free survival, and overall survival. The intention-to-treat populations from both trials were included in analyses. The PEMBRO-RT trial (NCT02492568) and the MDACC trial (NCT02444741) are registered with ClinicalTrials.gov. FINDINGS: Overall, 148 patients were included in the pooled analysis, 76 of whom had been assigned pembrolizumab and 72 who had been assigned pembrolizumab plus radiotherapy. Median follow-up for all patients was 33 months (IQR 32·4-33·6). 124 (84%) of 148 patients had non-squamous histological features and 111 (75%) had previously received chemotherapy. Baseline variables did not differ between treatment groups, including PD-L1 status and metastatic disease volume. The most frequently irradiated sites were lung metastases (28 of 72 [39%]), intrathoracic lymph nodes (15 of 72 [21%]), and lung primary disease (12 of 72 [17%]). Best ARR was 19·7% (15 of 76) with pembrolizumab versus 41·7% (30 of 72) with pembrolizumab plus radiotherapy (odds ratio [OR] 2·96, 95% CI 1·42-6·20; p=0·0039), and best ACR was 43·4% (33 of 76) with pembrolizumab versus 65·3% (47 of 72) with pembrolizumab plus radiotherapy (2·51, 1·28-4·91; p=0·0071). Median progression-free survival was 4·4 months (IQR 2·9-5·9) with pembrolizumab alone versus 9·0 months (6·8-11·2) with pembrolizumab plus radiotherapy (hazard ratio [HR] 0·67, 95% CI 0·45-0·99; p=0·045), and median overall survival was 8·7 months (6·4-11·0) with pembrolizumab versus 19·2 months (14·6-23·8) with pembrolizumab plus radiotherapy (0·67, 0·54-0·84; p=0·0004). No new safety concerns were noted in the pooled analysis. INTERPRETATION: Adding radiotherapy to pembrolizumab immunotherapy significantly increased responses and outcomes in patients with metastatic non-small-cell lung cancer. These results warrant validation in a randomised phase 3 trial. FUNDING: Merck Sharp & Dohme.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2020. PMID: 33096027. doi:10.1016/S2213-2600(20)30391-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。